Synthesising licensing data to assess drug safety

British Medical Journal

Volumn 328, Issue 7438, 2004, Pages 518-520

  McPherson, Klim ^a   Hemminki, Elina ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE ANALOG;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG FATALITY; DRUG LEGISLATION; DRUG MARKETING; DRUG PROGRAM; DRUG SAFETY; DRUG SCREENING; HORMONE SUBSTITUTION; HUMAN; LICENSING; MEDICAL INFORMATION; MEDICAL RECORD; MENOPAUSE; PATIENT COMPLIANCE; PATIENT INFORMATION; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SECONDARY PREVENTION; THROMBOEMBOLISM;

EID: 1442299034     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.328.7438.518     Document Type: Review

References (16)

1. Nurses' Health Study. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75.
2. Mathews KA, Meilahn BK, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989;321:641-6.
3. Daly E, Vessey D, Barlow A, Gray A, McPherson K, Roche M. Hormone replacement therapy in a risk-benefit perspective. Maturitas 1996;23: 247-59.
4. Writing Group of the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288;942-5.
5. Hemminki E, Malin M, Topo P. Selection to postmenopausal therapy by women's characteristics. J Clin Epidemiol 1993;46:211-9.
6. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980;303:1038-41.
7. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997;315:149-53.
8. Correspondence. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. BMJ 1997;315:676-9.
9. Naylor CD. Meta-analysis and the meta-epidemiology of clinical research. BMJ 1997;315:617-9.
10. Hemminki E, McPherson K. The value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease. Lancet 2000;355:566-9.
11. Roberts I, Po ALW, Chalmers I. Intellectual property, drug licensing, freedom of information and public health. Lancet 1998;352:726-9.
12. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:942-5.
13. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen plus progestins and the risks of coronary heart disease. N Engl J Med 2003;349:523-34.
14. Michels KB, Manson JE. Postmenopausal hormone therapy: a reversal of fortune. Circulation 2003;107:1830-3.
15. Skegg DCG, Doll R. The case for recording events in clinical trials. BMJ 1977;ii:1523-4.
16. Cuervo LG, Clarke M. Balancing benefits and harms in health care. We need to get better evidence about harms. BMJ 2003;327:65-6.